secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K
Filed at:   2022-07-14T23:59:59+00:00
Accession:  0001213900-22-039422
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Director Kuang-Tseng Chen resigns; Yu-Min (Francis) Chung appointed as director
-------------------------------------------------------------------------------

- Kuang-Tseng Chen resigned from the board on July 10, 2022, for personal reasons, effective immediately.
- Yu-Min (Francis) Chung appointed to fill the vacancy on the same day.
- Chung was a Partner at Maxpro Ventures (2018-2022) and VP at TaiAn Technology (2016-2018).
- Chung holds a Ph.D. in Pharmacy from the University of Iowa and an MBA from National Taiwan University.
- Directors receive $3,500 monthly compensation; no family relationships or material interests disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390022039422/0001213900-22-039422-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390022039422/ea162775-8k_abvcbio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-039422

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer